

NCT02867618 Raw comparison:

Summary:
CHIA has 17 criteria while your personal folder has 19 criteria
Total found criteria: 16/17
Total not Found: 1/17
Total Extra: 2
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Phase I Patients must have histologically          │ Phase I Patients must have histologically          │
│ confirmed R/R NHL or HL (defined by WHO criteria)  │ confirmed R/R NHL or HL (defined by World Health   │
│ Patients with chronic lymphocytic leukemia (CLL)   │ Organization (WHO) criteria) Patients with chronic │
│ and small lymphocytic lymphoma (SLL) are eligible  │ lymphocytic leukemia (CLL) and small lymphocytic   │
│ In addition patients with NHL other than diffuse   │ lymphoma (SLL) are eligible In addition patients   │
│ large B cell lymphomas (DLBCL) must have received  │ with NHL other than diffuse large B cell lymphomas │
│ at least 2 prior therapies Patients with DLBCL and │ (DLBCL) must have received at least 2 prior        │
│ HL will be eligible if there is no available       │ therapies Patients with DLBCL and HL will be       │
│ standard therapy                                   │ eligible if there is no available standard therapy │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Phase II Patients must have histologically         │ Phase II Patients must have histologically         │
│ confirmed R/R NHL (as defined by WHO criteria)     │ confirmed R/R NHL (as defined by WHO criteria)     │
│ Patients with NHL other than diffuse large B cell  │ Patients with NHL other than diffuse large B cell  │
│ lymphomas (DLBCL) must have received at least 2    │ lymphomas (DLBCL) must have received at least 2    │
│ prior therapies Patients with DLBCL will be        │ prior therapies Patients with DLBCL will be        │
│ eligible if there is no available standard therapy │ eligible if there is no available standard therapy │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Must have received front line chemotherapy No      │ Must have received front line chemotherapy No      │
│ upper limit for the number of prior therapies      │ upper limit for the number of prior therapies      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evaluable Disease in the Phase I and measurable    │ Evaluable Disease in the Phase I and measurable    │
│ disease in the Phase II                            │ disease in the Phase II                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age > 18 years                                     │ Age \> 18 years                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients must have adequate organ and marrow       │ Patients must have adequate organ and marrow       │
│ function                                           │ function                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Adequate Contraception                             │ Adequate Contraception                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ability to understand and the willingness to sign  │ Ability to understand and the willingness to sign  │
│ a written informed consent document                │ a written informed consent document                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior Therapy Exposure to chemotherapy or          │ Prior Therapy Exposure to chemotherapy or          │
│ radiotherapy within 2 weeks prior to entering the  │ radiotherapy within 2 weeks prior to entering the  │
│ study or those who have not recovered from adverse │ study or those who have not recovered from adverse │
│ events due to agents administered more than 2      │ events due to agents administered more than 2      │
│ weeks earlier Systemic steroids that have not been │ weeks earlier Systemic steroids that have not been │
│ stabilized (≥ 5 days) to the equivalent of ≤10     │ stabilized (≥ 5 days) to the equivalent of ≤10     │
│ mg/day prednisone prior to the start of the study  │ mg/day prednisone prior to the start of the study  │
│ drugs No other investigational agents are allowed  │ drugs No other investigational agents are allowed  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of allergic reactions to TGR-1202 or       │ History of allergic reactions to TGR-1202 or       │
│ carfilzomib                                        │ carfilzomib                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncontrolled inter-current illness                 │ Uncontrolled inter-current illness                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant women                                     │ Pregnant women                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Nursing women                                      │ Nursing women                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current malignancy or history of a prior           │ Current malignancy or history of a prior           │
│ malignancy                                         │ malignancy                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient known to be Human Immunodeficiency Virus   │ Patient known to be Human Immunodeficiency Virus   │
│ (HIV)-positive                                     │ (HIV)-positive                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active Hepatitis A Hepatitis B or Hepatitis C      │ Active Hepatitis A Hepatitis B or Hepatitis C      │
│ infection                                          │ infection                                          │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal   │
╞═══════════════════════════════════════╡
│ ECOG performance status < 2           │
╘═══════════════════════════════════════╛



╒═══════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                           │
╞═══════════════════════════════════════════════════════════════════╡
│ Must have minimum age of 18 Years                                 │
├───────────────────────────────────────────────────────────────────┤
│ Eastern Cooperative Oncology Group (ECOG) performance status \< 2 │
╘═══════════════════════════════════════════════════════════════════╛